Success Story

Gyroscope Therapeutics partners with a Penn gene therapy leader

Gyroscope Therapeutics, a British gene therapy company also located in Philadelphia, entered into a two-year sponsored research agreement with the Penn Center for Advanced Retinal and Ocular Therapeutics to develop gene therapies for serious eye diseases that can lead to permanent vision loss. 

The Center is led by Jean Bennett, PhD, whose lab developed and conducted the initial research on the gene therapy product now marketed by Spark Therapeutics under the brand name Luxturna for treatment of an inherited retinal disorder.  The two organizations plan to work together to explore specific gene therapy targets for glaucoma, optic neuritis and retinitis pigmentosa.

Skip to content